Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments
November 12, 2012 11:02 AM ESTSarepta Therapeutics (Nasdaq: SRPT) is trading higher Monday following a presentations by its Chief Medical Officer (CMO) at Action Duchenne, a Duchenne muscular dystrophy (DMD) event held in London this weekend.
According to reports from theStreet.com,... More
Sarepta (SRPT) to Update on Additional Eteplirsen Phase IIb Data
October 12, 2012 4:09 PM EDTSarepta Therapeutics (NASDAQ: SRPT) announced that data from a Phase IIb study evaluating eteplirsen, an investigational treatment for boys with Duchenne muscular dystrophy (DMD), will be presented Saturday, October 13th at the World Muscle Society in Perth, Australia. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Children's Hospital, will present the data in an oral presentation of the abstract titled, "Results at 48 Weeks of a Phase IIb Extension Study of the... More
Sarepta Therapeutics (SRPT) Moves Higher as Ex-FDA Official Sees Accelerated Approval
October 5, 2012 10:24 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT) is moving to the highs of the session and is nearly positive... More
